Teriflunomide reduces the Relapse Rate in Multiple Sclerosis

被引：0
|
作者：
Oberpichler-Schwenk, Heike [1 ]
Hess, Claudia [1 ]
Druckerei, W. Kohlhammer [1 ]
机构：
[1] GmbH Co KG, D-70329 Stuttgart, Germany
来源：
PSYCHOPHARMAKOTHERAPIE | 2011年 / 18卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：A1 / A2
页数：2
相关论文
共 50 条
  • [21] Mechanism of action of teriflunomide in multiple sclerosis
    Medina, S.
    Sainz de la Maza, S.
    Villarrubia, N.
    Alvarez-Lafuente, R.
    Alvarez-Cermeno, J. C.
    Arroyo, R.
    Monreal, E.
    Tejeda-Velarde, A.
    Rodriguez-Martin, E.
    Roldan, E.
    Costa-Frossard, L.
    Villar, L. M.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 265 - 266
  • [22] Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
    Norborg, H.
    Riise, T.
    Myhr, K. -M.
    Grytten, N.
    Wergeland, S.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 712 - 712
  • [23] Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
    Norborg, Hilde
    Riise, Trond
    Myhr, Kjell-Morten
    Grytten, Nina
    Wergeland, Stig
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (02)
  • [24] Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab
    Laursen, Julie Hejgaard
    Sondergaard, Helle Bach
    Sorensen, Per Soelberg
    Sellebjerg, Finn
    Oturai, Annette Bang
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 10 : 169 - 173
  • [25] A Tertiary Centre Experience on short term teriflunomide treatment outcome on Relapse Remitting Multiple Sclerosis(RRMS)
    Shahedah, K.
    Aghani, Rayhan A.
    Ng, C. F.
    Nafisah, Wan Nur W. Y.
    Tan, H. J.
    Rabani, R.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (03) : 474 - 474
  • [26] Effect of ponesimod compared with teriflunomide on treatment with concomitant corticosteroids for relapse in patients with relapsing forms of multiple sclerosis
    Obando, C.
    Turkoz, I.
    Simples, J., Jr.
    Doring, M.
    Ait-Tihyaty, M.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 595 - 595
  • [27] Daclizumab reduces the rate of brain atrophy in multiple sclerosis
    Borges, I.
    Shea, C.
    Ohayon, J.
    Bielekova, B.
    Reich, D.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S233 - S234
  • [28] Seasonal Variation of Relapse Rate in Multiple Sclerosis is Latitude Dependent
    Spelman, Tim
    Gray, Orla
    Trojano, Maria
    Petersen, Thor
    Izquierdo, Guillermo
    Lugaresi, Alessandra
    Hupperts, Raymond
    Bergamaschi, Roberto
    Duquette, Pierre
    Grammond, Pierre
    Giuliani, Giorgio
    Boz, Cavit
    Verheul, Freek
    Oreja-Guevara, Celia
    Barnett, Michael
    Grand'Maison, Francois
    Rio, Maria Edite
    Lechner-Scott, Jeannette
    Van Pesch, Vincent
    Fernandez Bolanos, Ricardo
    Flechter, Shlomo
    Den Braber-Moerland, Leontien
    Iuliano, Gerardo
    Amato, Maria Pia
    Slee, Mark
    Cristiano, Edgardo
    Laura Saladino, Maria
    Paine, Mark
    Vella, Norbert
    Kasa, Krisztian
    Deri, Norma
    Herbert, Joseph
    Moore, Fraser
    Petkovska-Boskova, Tatjana
    Alroughani, Raed
    Savino, Aldo
    Shaw, Cameron
    Vucic, Steve
    Santiago, Vetere
    Alejandra Bacile, Elizabeth
    Skromne, Eli
    Poehlau, Dieter
    Antonio Cabrera-Gomez, Jose
    Lucas, Robyn
    Butzkueven, Helmut
    ANNALS OF NEUROLOGY, 2014, 76 (06) : 880 - 890
  • [29] Teriflunomide in relapsing multiple sclerosis: therapeutic utility
    Freedman, Mark S.
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2013, 4 (05) : 192 - 205
  • [30] Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
    Bar-Or, Amit
    Pachner, Andrew
    Menguy-Vacheron, Francoise
    Kaplan, Johanne
    Wiendl, Heinz
    DRUGS, 2014, 74 (06) : 659 - 674
12345